Corvus Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Corvus Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($10.16M) | Nov 4, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($8.00M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($8.00M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | $15.19M | Nov 4, 2025 |
| Q2 | 2025 | Mar 31, 2025 | $15.19M | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | $15.19M | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($40.22M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($4.26M) | Aug 7, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($4.26M) | Nov 4, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($5.70M) | Nov 4, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.70M) | May 8, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($5.70M) | Aug 7, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($6.00M) | Nov 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($6.50M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($6.50M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($7.87M) | May 7, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($7.87M) | Aug 6, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($7.87M) | Nov 12, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($14.83M) | Nov 7, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($8.36M) | Nov 7, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($10.57M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($10.26M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($9.92M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($7.26M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($5.94M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($6.25M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($5.56M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($5.62M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($6.57M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($12.47M) | Nov 7, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($7.01M) | Aug 8, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($7.41M) | May 8, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($9.05M) | Nov 3, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($11.29M) | Aug 8, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($11.48M) | May 5, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($9.85M) | Nov 1, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($10.77M) | Aug 2, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($13.27M) | Apr 29, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($11.51M) | Oct 29, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($13.60M) | Jul 30, 2020 |